{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T20:29:24Z","timestamp":1786825764245,"version":"build-2736575974"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.bmc.2023.117499","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T21:58:51Z","timestamp":1697061531000},"page":"117499","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["A novel genetically-encoded bicyclic peptide inhibitor of human urokinase-type plasminogen activator with better cross-reactivity toward the murine orthologue"],"prefix":"10.1016","volume":"95","author":[{"given":"Ylenia","family":"Mazzocato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Perin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Morales-Sanfrutos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3873-3408","authenticated-orcid":false,"given":"Zhanna","family":"Romanyuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9813-4901","authenticated-orcid":false,"given":"Stefano","family":"Pluda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6495-0871","authenticated-orcid":false,"given":"Laura","family":"Acquasaliente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Borsato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"De Filippis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6114-9181","authenticated-orcid":false,"given":"Alessandro","family":"Scarso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5923-3843","authenticated-orcid":false,"given":"Alessandro","family":"Angelini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2023.117499_b0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.blre.2014.09.003","article-title":"Fibrinolysis and the control of blood coagulation","volume":"29","author":"Chapin","year":"2015","journal-title":"Blood Rev"},{"issue":"2","key":"10.1016\/j.bmc.2023.117499_b0010","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1160\/TH04-09-0592","article-title":"The urokinase plasminogen activator and its receptor. Role in cell growth and apoptosis","volume":"93","author":"Alfano","year":"2005","journal-title":"Thrombosis Haemostasis"},{"key":"10.1016\/j.bmc.2023.117499_b0015","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00024","article-title":"Multifaceted role of the urokinase-type plasminogen activator (uPA) and its receptor (uPAR): Diagnostic, prognostic, and therapeutic applications","volume":"8","author":"Mahmood","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.bmc.2023.117499_b0020","first-page":"15","article-title":"Proteolysis is the most fundamental property of malignancy and its inhibition may be used therapeutically","volume":"43","author":"Wyganowska-\u015awiatkowska","year":"2019","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.bmc.2023.117499_b0025","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.2174\/1389557518666180816110740","article-title":"Novel Inhibitors of Urokinase-type Plasminogen Activators: 4-(3H-imidazo[4,5-b]pyridin-2-yl)-N-Substituted Benzamide and Benzamidine Compound","volume":"18","author":"Ku\u015f","year":"2018","journal-title":"Mini-Rev Med Chem"},{"key":"10.1016\/j.bmc.2023.117499_b0030","doi-asserted-by":"crossref","first-page":"B055","DOI":"10.1158\/1535-7163.TARG-17-B055","article-title":"Abstract B055: New potential therapeutic applications of WX-UK1 as a specific and potent inhibitor of human trypsin-2 and human trypsin-3","volume":"17","author":"Oldenberg","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2023.117499_b0035","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3109\/00498254.2013.767481","article-title":"Activation of the anti-cancer agent upamostat by the mARC enzyme system","volume":"43","author":"Froriep","year":"2013","journal-title":"Xenobiotica"},{"key":"10.1016\/j.bmc.2023.117499_b0040","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/bjc.2013.62","article-title":"Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer","volume":"108","author":"Heinemann","year":"2013","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.bmc.2023.117499_b0045","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030498","article-title":"Therapeutic Strategies Targeting Urokinase and Its Receptor in Cancer","volume":"14","author":"Masucci","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bmc.2023.117499_b0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/DDDT.S285852","article-title":"Current status and perspectives of protease inhibitors and their combination with nanosized drug delivery systems for targeted cancer therapy","volume":"15","author":"Rudzi\u0144ska","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.bmc.2023.117499_b0055","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000151733","article-title":"Experience in phase I trials and an upcoming phase II study with uPA inhibitors in metastatic breast cancer","volume":"3","author":"Goldstein","year":"2008","journal-title":"Breast Care."},{"key":"10.1016\/j.bmc.2023.117499_b0060","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1200\/jco.2010.28.15_suppl.4060","article-title":"Randomized phase II trial with an uPA inhibitor (WX-671) in patients with locally advanced nonmetastatic pancreatic cancer","volume":"28","author":"Heinemann","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2023.117499_b0065","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1160\/TH04-11-0712","article-title":"Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UKI","volume":"93","author":"Setyono-Han","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.bmc.2023.117499_b0070","doi-asserted-by":"crossref","unstructured":"Oldenburg E, Schar RC, et al. Abstract 4200: New potential therapeutic applications of WX-UK1, as a specific and potent inhibitor of human trypsin-like protease. https:\/\/doi.org\/10.1158\/1538-7445.AM2018-4200.","DOI":"10.1158\/1538-7445.AM2018-4200"},{"key":"10.1016\/j.bmc.2023.117499_b0075","unstructured":"Stefan Sperl M, M, Buergle M, W, Schmalix G; K, Wosikowski P; B, Clement K. Hydroxyamidine and hydroxyguandine compounds as urolinase inhibitors. Patent No. US20060142305A1 2009;2(12)."},{"key":"10.1016\/j.bmc.2023.117499_b0080","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cbpa.2017.02.006","article-title":"Cyclic peptide therapeutics: past, present and future","volume":"38","author":"Zorzi","year":"2017","journal-title":"Curr Opin Chem Biol"},{"issue":"1","key":"10.1016\/j.bmc.2023.117499_b0085","article-title":"Therapeutic peptides: current applications and future directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduction Targeted Therapy"},{"key":"10.1016\/j.bmc.2023.117499_b0090","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.7150\/ijbs.21597","article-title":"Structural principles in the development of cyclic peptidic enzyme inhibitors","volume":"13","author":"Xu","year":"2017","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.bmc.2023.117499_b0095","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.2174\/0929867325666181016163630","article-title":"Small Peptides as Modulators of Serine Proteases","volume":"27","author":"Xu","year":"2018","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmc.2023.117499_b0100","doi-asserted-by":"crossref","first-page":"33613","DOI":"10.1074\/jbc.M314151200","article-title":"Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents","volume":"279","author":"Schweinitz","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2023.117499_b0105","first-page":"3063","article-title":"Interaction with the S1\u03b2-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors","volume":"14","author":"Wendt","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"10.1016\/j.bmc.2023.117499_b0110","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1021\/jm0300072","article-title":"Identification of Novel Binding Interactions in the Development of Potent, Selective 2-Naphthamidine Inhibitors of Urokinase. Synthesis, Structural Analysis, and SAR of N-Phenyl Amide 6-Substitution","volume":"47","author":"Wendt","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117499_b0115","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1164\/rccm.200903-0342OC","article-title":"Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model","volume":"181","author":"Henneke","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.bmc.2023.117499_b0120","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1021\/cb200478t","article-title":"Bicyclic peptide inhibitor reveals large contact interface with a protease target","volume":"7","author":"Angelini","year":"2012","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bmc.2023.117499_b0125","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1021\/acs.accounts.7b00184","article-title":"Phage Selection of Cyclic Peptides for Application in Research and Drug Development","volume":"50","author":"Deyle","year":"2017","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.bmc.2023.117499_b0130","doi-asserted-by":"crossref","first-page":"10187","DOI":"10.1021\/jm301276e","article-title":"Bicyclization and tethering to albumin yields long-acting peptide antagonists","volume":"55","author":"Angelini","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117499_b0135","doi-asserted-by":"crossref","first-page":"14414","DOI":"10.1002\/anie.201807298","article-title":"Orally Active Peptides: Is There a Magic Bullet?","volume":"57","author":"R\u00e4der","year":"2018","journal-title":"Angewandte Chemie - International Edition"},{"key":"10.1016\/j.bmc.2023.117499_b0140","doi-asserted-by":"crossref","first-page":"38424","DOI":"10.1074\/jbc.M505933200","article-title":"A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition","volume":"280","author":"Hansen","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2023.117499_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsb.2007.06.003","article-title":"Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1","volume":"160","author":"Zhao","year":"2007","journal-title":"J Struct Biol"},{"key":"10.1016\/j.bmc.2023.117499_b0150","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jmb.2011.07.028","article-title":"The binding mechanism of a peptidic cyclic serine protease inhibitor","volume":"412","author":"Jiang","year":"2011","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bmc.2023.117499_b0155","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1042\/BJ20071646","article-title":"A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: Changing species specificity by substitution of a single residue","volume":"412","author":"Andersen","year":"2008","journal-title":"Biochem J"},{"key":"10.1016\/j.bmc.2023.117499_b0160","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1021\/acs.jmedchem.8b01908","article-title":"Suppression of Tumor Growth and Metastases by Targeted Intervention in Urokinase Activity with Cyclic Peptides","volume":"62","author":"Wang","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117499_b0165","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nchembio.184","article-title":"Phage-encoded combinatorial chemical libraries based on bicyclic peptides","volume":"5","author":"Heinis","year":"2009","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bmc.2023.117499_b0170","doi-asserted-by":"crossref","first-page":"6562","DOI":"10.1021\/ja400461h","article-title":"Bicyclic peptide ligands pulled out of cysteine-rich peptide libraries","volume":"135","author":"Chen","year":"2013","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmc.2023.117499_b0175","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/anie.201309459","article-title":"Peptide ligands stabilized by small molecules","volume":"53","author":"Chen","year":"2014","journal-title":"Angewandte Chemie - International Edition."},{"issue":"22","key":"10.1016\/j.bmc.2023.117499_b0180","article-title":"Identification of target-binding peptide motifs by high-throughput sequencing of phage-selected peptides","volume":"42","author":"Rebollo","year":"2014","journal-title":"Nucl Acids Res"},{"key":"10.1016\/j.bmc.2023.117499_b0185","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1039\/C2MD20171B","article-title":"Phage display libraries of differently sized bicyclic peptides","volume":"4","author":"Rebollo","year":"2013","journal-title":"MedChemComm"},{"key":"10.1016\/j.bmc.2023.117499_b0190","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/cbic.201300228","article-title":"Improving binding affinity and stability of peptide ligands by substituting glycines with D-amino acids","volume":"14","author":"Chen","year":"2013","journal-title":"Chembiochem"},{"key":"10.1016\/j.bmc.2023.117499_b0195","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1158\/1535-7163.MCT-14-0534","article-title":"Bicyclic peptides conjugated to an albumin-binding tag diffuse efficiently into solid tumors","volume":"14","author":"Pollaro","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2023.117499_b0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2022.832418","article-title":"Role of Serine Proteases at the Tumor-Stroma Interface","volume":"13","author":"Tagirasa","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmc.2023.117499_b0205","doi-asserted-by":"crossref","unstructured":"Shih-Chi Su, Chiao-Wen Lin, Wei-En Yang. The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies. Expert Opin Therap Targets. Published online 2015:1\u201316. doi:10.1517\/14728222.2016.1113260.","DOI":"10.1517\/14728222.2016.1113260"},{"key":"10.1016\/j.bmc.2023.117499_b0210","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1021\/jm010244+","article-title":"Exploiting subsite S1 of trypsin-like serine proteases for selectivity: Potent and selective inhibitors of urokinase-type plasminogen activator","volume":"44","author":"Mackman","year":"2001","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117499_b0215","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/223426b0","article-title":"Protein inhibitors of proteinases","volume":"223","author":"Michael Laskowski","year":"1969","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2023.117499_b0220","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1074\/jbc.M110.204537","article-title":"Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1","volume":"286","author":"Lin","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2023.117499_b0225","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1074\/jbc.RA118.005419","article-title":"Biochemical and structural analyses suggest that plasminogen activators coevolved with their cognate protein substrates and inhibitors","volume":"294","author":"Jendroszek","year":"2019","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2023.117499_b0230","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00239-020-09959-9","article-title":"Evolutionary Aspects of the Structural Convergence and Functional Diversification of Kunitz-Domain Inhibitors","volume":"88","author":"Mishra","year":"2020","journal-title":"J Mol Evol"},{"key":"10.1016\/j.bmc.2023.117499_b0235","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1021\/ar0302282","article-title":"Loops, Linkages, Rings, Catenanes, Cages, and Crowders: Entropy-Based Strategies for Stabilizing Proteins","volume":"37","author":"Zhou","year":"2004","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.bmc.2023.117499_b0240","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1021\/acs.jcim.7b00355","article-title":"Ligand Strain and Entropic Effects on the Binding of Macrocyclic and Linear Inhibitors: Molecular Modeling of Penicillopepsin Complexes","volume":"57","author":"Su\u00e1rez","year":"2017","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmc.2023.117499_b0245","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nchembio.232","article-title":"The role of dynamic conformational ensembles in biomolecular recognition","volume":"5","author":"Boehr","year":"2009","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bmc.2023.117499_b0250","doi-asserted-by":"crossref","first-page":"15821","DOI":"10.1021\/acs.jpcb.5b11085","article-title":"Effects of Cyclization on Peptide Backbone Dynamics","volume":"119","author":"Wang","year":"2015","journal-title":"J Phys Chem B"},{"key":"10.1016\/j.bmc.2023.117499_b0255","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/bip.20983","article-title":"Conformational constraint in protein ligand design and the inconsistency of binding entropy","volume":"89","author":"Udugamasooriya","year":"2008","journal-title":"Biopolymers"},{"issue":"48","key":"10.1016\/j.bmc.2023.117499_b0260","doi-asserted-by":"crossref","DOI":"10.1002\/chem.202200465","article-title":"Structural and ITC Characterization of Peptide-Protein Binding: Thermodynamic Consequences of Cyclization Constraints, a Case Study on Vascular Endothelial Growth Factor Ligands","volume":"28","author":"Gaucher","year":"2022","journal-title":"Chem - A Eur J."},{"key":"10.1016\/j.bmc.2023.117499_b0265","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1002\/cbic.201300335","article-title":"Bicyclic peptide inhibitor of urokinase-type plasminogen activator: Mode of action","volume":"14","author":"Roodbeen","year":"2013","journal-title":"Chembiochem"},{"key":"10.1016\/j.bmc.2023.117499_b0270","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-biophys-070816-033743","article-title":"The Molecular Origin of Enthalpy\/Entropy Compensation in Biomolecular Recognition","volume":"47","author":"Fox","year":"2018","journal-title":"Annu Rev Biophys"},{"key":"10.1016\/j.bmc.2023.117499_b0275","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1021\/bc300184m","article-title":"Chemical macrocyclization of peptides fused to antibody Fc fragments","volume":"23","author":"Angelini","year":"2012","journal-title":"Bioconjug Chem"},{"issue":"1","key":"10.1016\/j.bmc.2023.117499_b0280","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-03687-x","article-title":"Directed evolution of broadly crossreactive chemokine-blocking antibodies efficacious in arthritis","volume":"9","author":"Angelini","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2023.117499_b0285","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1021\/cr960065d","article-title":"Phage display","volume":"901","author":"Smith","year":"1997","journal-title":"Chem Rev"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089623003474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089623003474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:24:38Z","timestamp":1760837078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089623003474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":57,"alternative-id":["S0968089623003474"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2023.117499","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel genetically-encoded bicyclic peptide inhibitor of human urokinase-type plasminogen activator with better cross-reactivity toward the murine orthologue","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2023.117499","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"117499"}}